Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab Phase 3 study in active hypereosinophilic syndrome
NL-OMON54266Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypereosinophilic syndrome (HES) comparing Benralizumab + standard of care, Placebo + standard of care and Open-label benralizumab extension (3 arms). Primary endpoint: Time to first HES worsening/flare. Started Jan 2023; status: recruiting.
02
Drugs
benralizumab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on NL-OMON54266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54266.